comparemela.com

Latest Breaking News On - Cincinnati comprehensive sickle cell center - Page 1 : comparemela.com

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

Aruvant to Participate in Multiple Conferences This Spring

Aruvant Announces ARU-1801 Data to be Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting

Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting April 27, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, April 27, 2021 /PRNewswire/ Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Dr. Punam Malik, director of the Cincinnati Comprehensive Sickle Cell Center and program leader of the Hematology and Gene Therapy Program at the Cincinnati Children’s Hospital Medical Center, will present data from the ARU-1801 Phase 1/2 MOMENTUM clinical trial during ASGCT, which will take place virtually from May 11 to May 14, 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.